<DOC>
	<DOCNO>NCT00381875</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response . Incomplete Freund 's adjuvant may stimulate immune system different way may help vaccine work well . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood . Giving vaccine therapy together incomplete Freund 's adjuvant GM-CSF may effective treatment patient HIV . PURPOSE : This clinical trial study well give vaccine therapy together incomplete Freund 's adjuvant GM-CSF work treat patient HIV .</brief_summary>
	<brief_title>Vaccine Therapy , Incomplete Freund 's Adjuvant , GM-CSF Treating Patients With HIV</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess safety vaccination comprise E1M184V peptide incomplete Freund 's adjuvant combination sargramostim ( GM-CSF ) patient HIV HLA-A2 positive . - Assess , preliminarily , ability E1M184V peptide vaccine induce cytotoxic T-cell response , define ELISPOT assay , patient . Secondary - Explore , preliminarily , effect regimen HIV viral load CD4 count patient . - Explore , preliminarily , development lamivudine emtricitabine resistance patient subsequently receive lamivudine emtricitabine . - Explore , preliminarily , ability E1M184V peptide vaccine induce cytotoxic T-cell response assess HLA-A2 class I tetramers intracellular interferon gamma production stimulation E1M184V . OUTLINE : This pilot study . Patients receive vaccination comprise E1M184V peptide incomplete Freund 's adjuvant subcutaneously ( SC ) day 1 week 0 , 4 , 8 , 12 , 16 . Patients also receive sargramostim ( GM-CSF ) SC immediately vaccination daily day 1-4 . Some patient receive GM-CSF first 2 dos vaccine . Treatment continue absence unacceptable toxicity . Patients undergo blood collection baseline 4 , 12 , 20 , 36 , 52 week biomarker/laboratory analysis . Assays may include immunoenzyme technique viral genotyping . After completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : HIV1 infection confirm Western blot enzymelinked immunosorbent assay HLAA2 positive polymerase chain reactionsequence specific primer CD4 Tcell count ≥ 300/mm³ Must receive stable regimen highly active antiretroviral therapy ( HAART ) include lamivudine emtricitabine ≥ 1 month prior study entry Patients HAART , include lamivudine emtricitabine , medically appropriate regimen include lamivudine emtricitabine , eligible willing change antiretrovirals Viral load &lt; 50 copies/mL 1 month prior study entry PATIENT CHARACTERISTICS : See Disease Characteristics ECOG performance status 01 Life expectancy ≥ 6 month Hemoglobin ≥ 9 g/dL WBC ≥ 1,000/mm³ Absolute neutrophil count ≥ 750/mm³ Platelet count ≥ 75,000/mm³ PT PTT ≤ 120 % control unless lupus anticoagulant detect Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ( ≤ 7.5 mg/dL direct fraction ≤ 0.7 mg/dL protease inhibitor therapy due Gilbert 's syndrome ) AST ALT ≤ 2.5 time ULN Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No hepatitis B surface antigen ( HBsAg ) prior history HBsAg lamivudine emtricitabine Prior treatment tenofovir currently HBsAg negative allow No evidence severe lifethreatening infection HIV within past 6 month No opportunistic infection require systemic therapy within past month No active malignancy , except basal cell carcinoma No known hypersensitivity incomplete Freund 's adjuvant incomplete Freund 's adjuvant VG ( vegetablegrade ) , E1M184V peptide , sargramostim ( GMCSF ) No abnormality would score ≥ grade 3 toxicity , except follow ( asymptomatic ) : Hyperuricemia grade 4 ( without physiologic consequence ) Elevation lactate dehydrogenase ≥ grade 3 Elevation creatine phosphokinase ( CPK ) ≥ grade 3 Hypophosphatemia ≥ grade 3 ( patient tenofovir ) Elevation alkaline phosphate grade 3 Hyperamylasemia ≥ grade 3 allow follow criterion meet : Macroamylasemia Lipase ≤ 2 time ULN Lymphopenia grade 3 No condition , opinion investigator , would preclude compliance study requirement PRIOR CONCURRENT THERAPY : See Disease Characteristics No systemic corticosteroid within past 3 week Concurrent systemic corticosteroid allow short term Physiologic replacement dos steroids allow No prior vaccination vaccine include part reverse transcriptase HIV1 No concurrent investigational drug vaccination No concurrent lamivudine emtricitabine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HIV infection</keyword>
</DOC>